Quest pays $13 million to US government:
This article was originally published in Clinica
Quest Diagnostics has agreed to a $13.1 million settlement relating to US federal healthcare fraud allegations against its Nichols Institute. The billing and marketing practices in question took place from 1989 - Quest bought Nichols in 1994 and says they were stopped shortly after. The government says that clinical laboratories billed for tests that were not medically necessary. Quest denies the government's claims, arguing that the government had identified the practices as "common industry practices". The cost of the settlement will be covered by Corning, Quest's parent at the time of the Nichols acquisition.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.